Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity.

ABSTRACT:

Introduction

IL-15 agonists hold promise as immunotherapeutics due to their ability to induce the proliferation and expansion of cytotoxic immune cells including natural killer (NK) and CD8⁺ T cells. However, they generally have short half-lives that necessitate frequent administration to achieve efficacy. To address this limitation, we have developed a half-life extension technology using hydrogel microspheres (MS). Here, the therapeutic is tethered to MSs by a releasable linker with pre-programed cleavage rates. We previously showed the MS conjugate of single-chain IL-15, MS~IL-15, effectively increased the half-life of IL-15 to approximately 1 week and enhanced the pharmacodynamics. We sought to determine whether the same would be true with a MS conjugate of the IL-15

SUBMITTER: Hangasky JA 

PROVIDER: S-EPMC11570272 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature